Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

August 10, 2018: By Jon Swedien

Allergan will co-develop and commercialize Editas Medicine’s experimental CRISPR genome editing medicine for Leber congenital amaurosis type 10 (LCA10), the drugmaker announced Aug. 8.

The companies will share equally in US profits and losses of the LCA10 candidate, EDIT-101.

Allergan paid Editas $15 million to exercise its option to develop EDIT-101 under terms outlined in an agreement the two companies signed in 2017. Editas will receive an additional $25 million if the US FDA accepts Allergan’s investigational new drug (IND) application for EDIT-101.

Dublin-based Allergan had the option to license up to five of Editas Medicine’s genome editing programs for ocular diseases under the 2017 agreement. Also, Editas had the option to co-develop and share equal profits for two of the candidates, which it has chosen to do with EDIT-101.

Editas, of Cambridge, Massachusetts, is eligible to receive development and commercial milestones and royalty payments on a per-program basis where the parties are not sharing profits and losses.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Astellas Acquires Quethera, Glaucoma Gene Therapy Candidate in Potential $109 Million Deal

STAAR Surgical Completes $77.9 Million Public Offering

Rheon’s eyeWatch Adjustable Glaucoma Device Implanted in Three UK Patients

Carl Zeiss Meditec Revenues Total $356 Million in Third Quarter of FY2018, a 12.7 Percent Increase

Kedalion Therapeutics Raises $5 Million in Series A Financing

Second Sight Reports 17 Argus II Implantations in Q2-2018; Firm to Focus on Orion System

Iridex Revenues Grow 3 Percent in Q2-2018

Omeros Revenues Drop Steeply with Omidria’s Temporary Loss of Pass-through Status

Shire’s Xiidra Delivers $100 Million in Q2-2018 Revenues, an Increase of 75 Percent

STAAR Posts Q2-2018 Revenues of $33.9 Million, a 55 Percent Increase

Avedro Names Glaukos CEO Thomas Burns to its Board

Aerie Licenses DSM’s Bioerodible Implant Technology for Ophthalmic Use for $15 Million

Alimera’s Q2-2018 Revenues Increase 5 Percent

Presbyopia Therapies’ PRX Meets Phase IIb Endpoints

Clinical Study of Imprimis’ Dropless Formulation Set to Begin in Canada

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT